Ganoderic acid modulating TNF and its receptors: in silico and in vitro study

Abstract

Cancer is a multifactorial disease with a network of genes causing genetic alterations. The sophisticated techniques in molecular biology revealed different cancer pathway, but their mechanistic approach is still shrouded. Tumor necrosis factor and TNF-related apoptosis-inducing ligand receptors (DR5) emerged as potential target drug for the cancer therapy. Among natural products basidiomycete fungus, Ganoderma lucidum and its constituents endowed with a plethora of activities modulating signaling in cancer. Ganoderic acid, a triterpene with lanosteroidal skeleton play an inextricable role in modulating signaling cascades in various mitogenic pathways. In the present study, receptor-based molecular docking was performed to study the dynamic behavior of the docked complexes and the molecular interactions between ganoderic acid and its isoforms with tumor necrosis factor and its receptor (DR5). The top scoring compounds were compared with the already documented natural inhibitor of tumor necrosis factor, DR5-curcumin, catechin, bupropion, pentoxyphyllin for their binding affinity and other absorption, distribution, metabolism, excretion, and toxicity properties. Ganoderic acid A interact more promising as compared with other isoforms with GScore (−9.858 (kcal/mol), Lipophilic EvdW (−1.7), H Bond (−0.9), Glide emodel (−40.5) with the involvement of Tyr 151, Leu 120 and Gln 149 residues during binding with tumor necrosis factor. During docking of ganoderic acid with DR5, ganoderic acid A exhibits GScore (−8.7), HBond (−2.9), Glide emodel (−30.0) with the involvement of hydrogen bonding inMet99, Arg101, Pro97, Glu98 residues. Natural inhibitors already documented exhibit low-binding energy and other docking parameters, which have an edge of ganoderic acid A to tumor necrosis factor and DR5. Ganoderic acid A efficiently inhibits the proliferation, viability, and intracellular reactive oxygen